Manufacturer
AstraZeneca Pharmaceuticals LP
Contents
Daclatasvir
Indication
Chronic hepatitis C.
Instruction
May be taken with or without food.
Drug interaction
May cause severe bradycardia and heart block when concomitantly used w/ amiodarone (in conjunction w/ sofosbuvir). Decreased plasma concentration and therapeutic effect w/ moderate CYP3A4 enzyme inducers. Increased plasma concentration w/ strong CYP3A4 enzyme inhibitors (e.g. clarithromycin, itraconazole, ketoconazole, ritonavir). May increase systemic exposure to drugs that are substrates of P-gp transporter (e.g. digoxin), OATP 1B1/1B3, and BCRP.Potentially Fatal: Decreased plasma concentration and therapeutic effect w/ strong CYP3A4 enzyme inducers (e.g. carbamazepine, phenytoin, rifampicin).
Malaysia
